Posaconazole and Ritlecitinib interaction
Posaconazole and Ritlecitinib: both prescribing labels mention this combination without an instruction to avoid it or change the dose.
Mentioned, no instruction to avoid. Worth knowing; rarely a reason to change anything on its own.
What the FDA labels say
From the Posaconazole (NOXAFIL) label · effective 2026-02-13
CYP3A Substrates Immunosuppressants that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Posaconazole is a strong CYP3A4 inhibitor.
From the Ritlecitinib (Litfulo) label · effective 2026-06-17
Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.